STC-15 is under clinical development by Storm Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how STC-15’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

STC-15 overview

STC-15 is under development for the treatment of acute myeloid leukaemia (AML) and other solid cancers. The drug candidate acts by targeting methyltransferase-like protein 3 (METTL3). It is administered through an oral route.

Storm Therapeutics overview

Storm Therapeutics. (STORM) is a clinical-stage biotechnology company that discovers and develops novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases. The company’s pipeline products include METTL3 (STC-15), ADARI (Exelixis) and UKRI. Its pipeline candidates treat oncology and, covid -19 viral infection. STORM is funded by M Ventures, Pfizer, Taiho Ventures, LLC, Seroba, Cambridge Innovation Capital, IP Group, The University of Tokyo IPC and Fast Track Initiative . Storm Therapeutics is headquartered in Cambridge, England, the UK.

For a complete picture of STC-15’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.